Shares of Moderna Inc. (MRNA) surged 5.03% in Friday's trading session amidst positive news for the biotech company.
In a vote of confidence, Moderna CEO Stephane Bancel and board member Paul Sagan purchased over $6 million worth of the company's shares this week according to SEC filings. Additionally, Moderna secured a favorable legal outcome in a patent dispute with Pfizer and BioNTech over its Covid-19 vaccine technology. A German court ruled that the two pharma giants infringed on Moderna's patented technology, requiring them to compensate the biotech firm, with the amount to be determined in further proceedings.
The insider buying and legal victory likely fueled investor optimism and drove Moderna's stock higher in Friday's trading. The episode highlights confidence from leadership as well as bolstered prospects for future revenue streams from the patent win against rivals.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。